November 11, 2021 06:43 PM Eastern Daylight Time
BUSINESS WIRE
Celltrion riceve l'opinione positiva del CHMP per regdanvimab (CT-P59), rientrando tra i primi anticorpi monoclonali raccomandati dal CHMP come trattamento del COVID-19
Tweet
View Full Size
Download
Full Size
JPEG
,
2526
x
822
,
153.4 KB
Small
JPEG
,
480
x
156
,
24.8 KB
Preview
JPEG
,
144
x
47
,
5.3 KB
Thumbnail
JPEG
,
120
x
39
,
3.7 KB
Smart Multimedia Gallery
Share
Facebook
Twitter
LinkedIn
Delicious
Reddit
StumbleUpon
Digg
MySpace
Newsvine
Google Bookmark
Yahoo! Bookmark
Email
All News
|
News with Multimedia
>
Press Release: Celltrion riceve l'opinione positiva del CHMP ...